B. Braun Melsungen
| B. Braun Melsungen AG
|
|
|---|---|
 |
|
| legal form | Corporation |
| founding | June 23, 1839 |
| Seat | Melsungen , Germany |
| management | Anna Maria Braun ( CEO ) |
| Number of employees | 64,585 (2019) |
| sales | 7.471 billion euros (2019) |
| Branch | Pharmaceutical and medical products, medical technology |
| Website | www.bbraun.de |
The B. Braun Melsungen AG is a German pharmaceutical and medical needs company with headquarters in Melsungen in the Schwalm-Eder district in Hesse .
History and Development
The B. Braun company was founded by the Rosen Pharmacy. This was acquired on June 23, 1839 for 14,000 thalers from Julius Wilhelm Braun in Brückenhofstrasse in Melsungen.
His son Bernhard Braun began producing plasters and migraine pens in 1864. In 1867 the pharmacy was separated from the production of pharmaceutical products and the company was entered in the commercial register under the current name of B. Braun . In 1900 Carl Braun took over the pharmacy and the company from his father. In 1908 the company began producing suture material from sterile, absorbable mutton intestines ( catgut ). This was followed by the production of fracture splints for bone fracture treatment .
The first blood pressure monitors were manufactured in 1914 . In 1923 the company health insurance fund B. Braun Melsungen was founded by Carl Braun. The first foreign production facility was set up in Milan in 1925. In 1930 the development of the modified Tyrode solution Sterofundin began, the basis for all later full electrolyte solutions at B. Braun. In 1935 the production of Synthofil A, an unabsorbable synthetic suture material, began.
Otto Braun took over the business in 1929 , and Bernhard Braun became scientific director in 1937 . The two brothers pursued the expansion of the company and expanded the product range; In 1939 the factory had 500 employees.
During the Second World War, the company employed forced labor from the AEL-Breitenau . The Jewish doctor Lilli Jahn , mother of Gerhard Jahn, was one of these forced laborers .
post war period
After the Second World War , the first infusion pumps and infusion devices made of glass were developed.
In 1949, Supramid-Braun, a nylon-based surgical suture material, was launched. 1955 was the Spanish Rubi in Barcelona a work for suture material under the name Clínico, S.A. (now B. Braun Medical, S. A.) was founded. The Braunüle used plastic as a material for the first time in 1962 as a one-piece infusion cannula . With around 1700 employees, sales rose to DM 50 million by 1964 . In 1966 the B. Braun Foundation was established to promote the training and further education of doctors and nursing staff. The foundation's capital comes from the sales of the specialist magazine “Die Sister” (today: “Die Sister, der Pfleger”).
In 1968 Otto and Bernhard Braun transferred 90 percent of the shares to their children with usufruct . In a second step, after the company was converted into a stock corporation in 1971 , the remaining ten percent was transferred to the grandchildren in 1983. During this phase, Ludwig Georg Braun , son of Otto Braun, became the spokesman for the board in 1977 .
Further production facilities were established in Malaysia (1972), France (1976) and in the USA (1979).
In 1976, B. Braun acquired Aesculap AG from Tuttlingen and achieved an annual turnover of DM 425 million. The number of employees rose to around 3,100 with the takeover. As early as 1998, sales exceeded the four billion DM mark with 27,000 employees.
In 1992 a new work was designed by the architect James Stirling and inaugurated on the "Pfieffewiesen" site in Melsungen.
In the 1990s it became known that the companies Braun and Biodynamics had meninges delivered from Berlin hospitals for the manufacture of medicinal products. In February 1996, the head of pathology at the Berlin University Clinic, Rudolf Virchow , accused Braun Melsungen of having “received HIV- infected material” for the manufacture of medicinal products from human meninges . From 1989 to 1994 3500 meninges from eight Berlin hospitals were illegally delivered to the Braun company and 500 to the Biodynamics company in Erlangen. For the Lyodura product, Braun had also processed meninges from tuberculosis patients , hepatitis infected people and dead people with metastases in the brain.
Meningeal transplants with the plaster material Lyodura , which was manufactured by B. Braun, resulted in around 120 infections with Creutzfeldt-Jakob disease - mostly in Japan - by 2004 . Due to inadequate controls of the meninges donors and the manufacturing process, in which meninges were insufficiently disinfected and stacked in stacks, healthy meninges were cross-contaminated with prions. Lyodura was used as a kind of "plaster" during operations, especially since it was characterized by low rejection reactions. After an unsuccessful change in the manufacturing process, B. Braun ended production in Germany in 1996; Similar products from other manufacturers were withdrawn from the market in the USA and Canada in 2002. In the same year, B. Braun Melsungen agreed with the Japanese health authorities to pay compensation to the families of the victims in the amount of more than 600,000 US dollars each.
A logistical alliance with the Hartmann Group has existed since 2000 . In 2004, B. Braun Melsungen acquired Saxonia Medical in Radeberg , a production facility for dialyzers, and in 2005, Ascalon in Berggießhübel (manufacture of hollow fiber membranes for dialyzers). In 2009, a drug- coated balloon catheter was launched , which improves blood flow to the coronary arteries .
In February 2012, the company announced that it would no longer sell human insulin .
In 2019 Anna Maria Braun, the daughter of Ludwig Georg Braun, took over the chairmanship of the group from Heinz-Walter Große.
Todays situation
In the 2019 financial year, annual sales amounted to 7.471 billion euros. The company employs 64,585 people in 64 countries and is owned by the founding family. The headquarters are in Melsungen in northern Hesse, the chairman of the board is Anna Maria Braun.
In August 2012, the Rhön Clinics announced that B. Braun Melsungen had acquired five percent of the shares.
Divisions
B. Braun has divided its business into four divisions:
- Hospital Care equips hospitals and is a leader in clinical care and inpatient care products.
- Aesculap is the world market leader for hand-held surgical instruments.
- Out Patient Market (OPM) takes care of patient care outside of hospital operations and for chronically ill or long-term patients.
- B. Braun Avitum is one of three global full-service providers of extracorporeal blood treatment.
subsidiary company
The company's Swiss subsidiary is B. Braun Medical AG , which develops and manufactures medical products. It is one of the 500 largest Swiss companies and employs almost 1,000 people at its four locations in Crissier , Escholzmatt , Lucerne and Sempach . In Escholzmatt, around 250 employees produce medical plastic disposable items for infusion products .
Further subsidiaries are:
- Aesculap
- TransCare Service GmbH
Board
The board consists of
- Anna Maria Braun, CEO
- Dr. Annette Beller
- Dr. Meinrad Lugan
- Caroll H. Neubauer
- Dr. Joachim Schulz
- Markus Strotmann
- Dr. Stefan Ruppert (Deputy Member)
Literature (selection)
- Karl Philipp Behrendt: War surgery from 1939 to 1945 from the perspective of the consulting surgeons of the German Army in World War II , doctoral thesis, 2003, p. 87 (PDF; 2.2 MB), accessed on May 1, 2012
Web links
Individual evidence
- ↑ a b c bbraun.de: 2019 - The financial year in figures, accessed on March 27, 2020.
- ^ Trademark register - Sterofundin
- ↑ trademark register - Synthofil
- ↑ Markus Plate, Thorsten Groth, Volker Ackermann, Arist von Schlippe: Large German family businesses: Generational succession, family strategy and corporate development. Göttingen 2011. 1 edition, p. 54f.
- ^ Guxhagen (Breitenau Abbey). In: tenhumbergreinhard.de. Accessed December 31, 2017 .
- ^ The sister, the carer , ISSN 0340-5303 , online, accessed September 17, 2014
- ↑ Contaminated Raw Material, Focus Magazine, Issue 12, 1996
- ↑ Ludwig Georg Braun: Christian provocateur. In Focus, April 23, 2004
- ↑ F. Brooke, A. Boyd, GM Klug, CL Masters, SJ Collins: Lyodura use and the risk of iatrogenic Creutzfeldt-Jakob disease in Australia. Med. J. Aust., February 16, 2004; 180 (4): 177-81.
- ^ Friedemann Hottenbacher: German pharmaceutical company sued in Japan. Report in the taz from March 25, 1998.
- ↑ a b Health Canada bans 'brain patch' linked to brain disease. CBC News, April 15, 2002.
- ↑ Diabetes: B. Braun stops selling insulin and concentrates on the further development of blood glucose meters and pen needles ( memento of the original from June 7, 2012 in the Internet Archive ) Info: The archive link was automatically inserted and not yet checked. Please check the original and archive link according to the instructions and then remove this notice. , accessed April 29, 2012
- ↑ RHÖN-KLINIKUM AG: Release according to Article 26, Section 1 of the WpHG with the aim of Europe-wide distribution. August 27, 2012.
- ↑ Florian Langenscheidt , Bernd Venohr (Hrsg.): Lexicon of German world market leaders. The premier class of German companies in words and pictures . German Standards Editions, Cologne 2010, ISBN 978-3-86936-221-2 .
- ↑ Four locations in Switzerland , on the B. Braun Medical AG website, accessed on April 23, 2017
- ↑ Imprint. Retrieved April 20, 2019 .
